A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma-Reference-Cited by-同舟云学术

A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma

Published:2014-08 Issue:4 Volume:12 Page:241-250
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Bitting Rhonda L.,Healy Patrick,Creel Patricia A.,Turnbull James,Morris Karla,Wood Sarah Yenser,Hurwitz Herbert I.,Starr Mark D.,Nixon Andrew B.,Armstrong Andrew J.,George Daniel J.

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference57 articles.

1. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004

2. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane;Burstein;J Clin Oncol,2008

3. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer;Miller;N Engl J Med,2007

4. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer;Miller;J Clin Oncol,2005

5. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N Engl J Med,2006

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multifunctional nanocarrier-mediated approaches and conventional therapies for effective treatment of cancer;Multifunctional Nanocomposites for Targeted Drug Delivery in Cancer Therapy;2024

2. Advances in Drug Therapy for Gastrointestinal Stromal Tumour;Current Medicinal Chemistry;2023-05-05

3. Playing the Devil’s Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? – ie Strategies to Revert Resistance to mTOR Inhibitors;Cancer Management and Research;2021-10

4. Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer;Critical Reviews in Oncology/Hematology;2021-07

5. Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study;Investigational New Drugs;2021-03-18